ClinicalTrials.Veeva

Menu

Safety of Celecoxib in Patients With Crohn's Disease

University of Pittsburgh logo

University of Pittsburgh

Status and phase

Terminated
Phase 4

Conditions

Crohn's Disease

Treatments

Drug: placebo
Drug: Celebrex

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT00177866
0312013

Details and patient eligibility

About

The investigators will select 60 people who are 18-70 years of age with Crohn's disease and randomly assign them to receive an 8-week trial of celecoxib and an 8-week trial of a placebo. There will be a 1-week interval or "wash-out" between trials when the participant does not take any study medication. The investigators will monitor the participants for 18 weeks after they start the medication and observe their Crohn's disease activity, assessing for flare-ups or exacerbations in the disease and other possible side effects of celecoxib. Based on these observations, a determination will be made by the investigators as to the safety of celecoxib. If celecoxib is found to be safe, then it may provide physicians with a medication that they can prescribe for people who have Crohn's disease and experience chronic pain from arthritis and arthralgia.

Full description

Please refer to brief summary (above).

Enrollment

28 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Greater than 18 years of age or less than 70 years of age
  2. Confirmed diagnosis of Crohn's disease
  3. Inactive disease (CDAI scores at baseline <150) or active disease (CDAI scores at baseline <200).

Exclusion criteria

  1. Pregnant, nursing mothers and women of childbearing potential who are not using reliable contraception (i.e.: oral contraceptive pill [OCP], intrauterine device [IUD], Norplant)
  2. Enrolled in any other study involving non-steroidal anti-inflammatory drug (NSAID) medications
  3. NSAID use at time of study
  4. Baseline moderate to severe Crohn's disease activity (CDAI > 200)
  5. Current treatment of less than 6 months with mercaptopurine (6 MP) or immuran.
  6. Treatment with current Crohn's medication for a period of less than 3 months
  7. Surgery for Crohn's disease (within 1 month)
  8. Known sensitivity to celecoxib, NSAIDs, or sulfonamides
  9. History of gastritis, gastrointestinal bleeding, or peptic ulcer disease
  10. Advanced kidney disease
  11. Severe hepatic impairment
  12. Subjects currently taking angiotensin-converting enzyme (ACE) inhibitors, furosemide, fluconazole, lithium, corticosteroids, and warfarin

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Triple Blind

28 participants in 2 patient groups, including a placebo group

A Placebo or Celebrex
Active Comparator group
Description:
either placebo PO BID for the first eight weeks or Celebrex 200 mg PO BID for the first eight weeks
Treatment:
Drug: Celebrex
B Placebo or Celebrex
Placebo Comparator group
Description:
either placebo PO BID for the last eight weeks or Celebrex 200 mg PO BID for the last eight weeks
Treatment:
Drug: placebo

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems